LipoScience Company Profile (NASDAQ:LPDX)

About LipoScience

LipoScience logoLipoScience, Inc. is a vitro diagnostic company. The Company's diagnostic test, the nuclear magnetic resonance (NMR) LipoProfile test, directly measures the number of low density lipoprotein (LDL), particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. The Company's Vantera system is the Company's automated clinical analyzer. As of January 25, 2013, over eight million NMR LipoProfile tests were ordered. The Vantera system is its automated clinical analyzer. In August 2012, the Company received Food and Drug Administration (FDA) clearance to market the Vantera system commercially to laboratories.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: LPDX
  • CUSIP: 53630M10
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $0
  • 200 Day Moving Average: $4
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.24
  • P/E Growth: 0
  • Market Cap: $N/A
Additional Links:
Companies Related to LipoScience:

Analyst Ratings

Consensus Ratings for LipoScience (NASDAQ:LPDX) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for LipoScience (NASDAQ:LPDX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for LipoScience (NASDAQ:LPDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/12/2014Q3 14($0.26)($0.28)ViewN/AView Earnings Details
8/12/2014($0.24)($0.27)ViewN/AView Earnings Details
5/12/2014Q1 14($0.19)($0.13)ViewN/AView Earnings Details
3/10/2014Q413($0.24)($0.17)$12.71 million$12.72 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for LipoScience (NASDAQ:LPDX)
Current Year EPS Consensus Estimate: $-0.93 EPS
Next Year EPS Consensus Estimate: $-0.84 EPS

Dividends

Dividend History for LipoScience (NASDAQ:LPDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for LipoScience (NASDAQ:LPDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/4/2013Daniel LevangieDirectorBuy10,000$4.17$41,700.00View SEC Filing  
12/4/2013E. Duffy McdonaldVPSell12,731$4.07$51,815.17View SEC Filing  
11/25/2013James HurleyDirectorBuy5,100$3.91$19,941.00View SEC Filing  
11/18/2013Robert Greczyn, Jr.CEOBuy10,000$4.15$41,500.00View SEC Filing  
1/30/2013Buzz BensonDirectorBuy50,000$9.00$450,000.00View SEC Filing  
1/30/2013Three Arch Capital LpMajor ShareholderBuy215,000$9.00$1,935,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for LipoScience (NASDAQ:LPDX)
DateHeadline
finance.yahoo.com logoMiraculins: Pioneering a New Approach to Diabetes Screening (NASDAQ:LPDX)
finance.yahoo.com - January 27 at 8:00 AM
finance.yahoo.com logoUS STOCKS-Cantor turns bearish on U.S. equities (NASDAQ:LPDX)
finance.yahoo.com - September 25 at 10:27 AM

Social

What is LipoScience's stock symbol?

LipoScience trades on the NASDAQ under the ticker symbol "LPDX."

How do I buy LipoScience stock?

Shares of LipoScience can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of LipoScience stock cost?

One share of LipoScience stock can currently be purchased for approximately $5.24.

LipoScience (NASDAQ:LPDX) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for LipoScience (NASDAQ:LPDX)

Earnings History Chart

Earnings by Quarter for LipoScience (NASDAQ:LPDX)

Dividend History Chart

Dividend Payments by Quarter for LipoScience (NASDAQ:LPDX)

Last Updated on 2/19/2017 by MarketBeat.com Staff